Participant flow14

How many started, completed or left each group, period by period.

1 to 14 of 14

Period	Milestone	Group	Participants
Treatment Period	STARTED	CC-486 200 mg	6
Treatment Period	STARTED	CC-486 300 mg	30
Treatment Period	Investigational Product (IP) Stopped	CC-486 200 mg	6
Treatment Period	Investigational Product (IP) Stopped	CC-486 300 mg	30
Treatment Period	COMPLETED	CC-486 200 mg	0
Treatment Period	COMPLETED	CC-486 300 mg	0
Treatment Period	NOT COMPLETED	CC-486 200 mg	6
Treatment Period	NOT COMPLETED	CC-486 300 mg	30
Follow-Up Survival Period	STARTED	CC-486 200 mg	5
Follow-Up Survival Period	STARTED	CC-486 300 mg	26
Follow-Up Survival Period	COMPLETED	CC-486 200 mg	0
Follow-Up Survival Period	COMPLETED	CC-486 300 mg	0
Follow-Up Survival Period	NOT COMPLETED	CC-486 200 mg	5
Follow-Up Survival Period	NOT COMPLETED	CC-486 300 mg	26

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT02269943/flow